Valuation : CorMedix Inc.

Market Cap 620M 534M 503M 459M 857M 59.32B 865M 6B 2.31B 30.09B 2.33B 2.28B 95.57B P/E 2026 *
16.3x
P/E 2027 * 133x
Enterprise Value 620M 534M 503M 459M 857M 59.32B 865M 6B 2.31B 30.09B 2.33B 2.28B 95.57B EV / Sales 2026 *
1.84x
EV / Sales 2027 * 2.17x
Free-Float
92.45%
Yield 2026 *
-
Yield 2027 * -
1 day-2.09%
1 week-6.02%
Current month-3.63%
1 month+5.71%
3 months-9.24%
6 months+18.45%
Current year-31.56%
1 week 7.92
Extreme 7.92
8.37
1 month 7.1
Extreme 7.1
8.98
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
13.3
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Compliance Officer 66 12/12/2023
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
29/8/26 Tax

Chief Financial Officer

-8,424 0.0108%
29/8/26 Tax

Compliance Officer

-8,424 0.0108%
29/8/26 Tax

Chief Operating Officer

-8,076 0.0104%
Change 5-day change 1-year change 3-year change Capi.($)
-2.09%-6.02%-37.76%+115.14% 634M
-1.91%-5.01%+72.21%+32.70% 364B
-0.79%-4.50%+21.22%-20.04% 67.05B
-0.36%-3.39%+41.16%+177.85% 12.19B
-1.63%-9.78%-12.63%-17.12% 7.58B
-0.48%-3.47%-23.84%+1.83% 4.9B
-1.38%-3.07%-33.97%+13.49% 4.45B
-2.27%-6.14%-35.86%-9.87% 2.96B
-0.90%-5.19%-9.78%+36.29% 2.45B
-1.17%-3.71%-25.81%-20.42% 1.96B
Average -1.30%-4.28%-4.51%+30.98% 46.82B
Weighted average by Cap. -1.68%-3.07%+59.04%+27.25%

Financials

2026 *2027 *
Net sales 337M 290M 274M 249M 466M 32.23B 470M 3.26B 1.25B 16.35B 1.27B 1.24B 51.92B 286M 246M 232M 212M 396M 27.39B 399M 2.77B 1.07B 13.89B 1.08B 1.05B 44.12B
Net income 45.66M 39.27M 37.05M 33.75M 63.1M 4.37B 63.67M 441M 170M 2.21B 171M 168M 7.03B 5.69M 4.89M 4.61M 4.2M 7.86M 544M 7.93M 54.95M 21.15M 276M 21.35M 20.88M 876M
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
10/09/26 USD 7.960 -2.09% 857,254
09/09/26 USD 8.130 -0.61% 928,241
08/09/26 USD 8.180 -2.97% 1,101,106
04/09/26 USD 8.430 -0.47% 792,913
03/09/26 USD 8.470 -1.63% 707,673
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.960USD
Average target price
15.40USD
Spread / Average Target
+93.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!